A multi-institutional study analyzing effect of a novel lozenge containing polaprezinc for patients treated with high dose chemotherapy followed by hematopoietic stem cell transplantation

A multi-institutional study analyzing effect of a novel lozenge containing polaprezinc for patients treated with high dose chemotherapy followed by hematopoietic stem cell transplantation - A multi-institutional study analyzing effect of polaprezinc lozenge

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025524

Enrollment

100

Registered

2017-01-04

Start date

2017-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancy

Interventions

Prevention group Intervention periods:35 days Treatment group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients with hematopoietic malignancy receiving high dose chemotherapy followed by hematopoietic stem cell transplantation 2 Patients with ECOG performance ststus under 2 3 Patients aged over 18 years and under 90

Exclusion criteria

Exclusion criteria: 1 Patients aged under 18 years 2 Patients with oral mucositis at the start of chemotherapy

Design outcomes

Primary

Measure	Time frame
Incidence of grade>2 oral mucositis during 35 days after start of chemotherapy	—

Countries

Japan

Contacts

Public ContactAkio Suzuki

Gifu University Hospital Department of Pharmacy

akio@gifu-u.ac.jp058-230-7091

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026